Original from: genomeweb

Zydus Lifesciences said on Friday that it has signed an agreement to exclusively commercialize a trio of Myriad Genetics cancer tests in India.

The deal covers Myriad's MyRisk Hereditary Cancer Test with Risk Score for predicting hereditary cancer risk; its MyChoice HRD Plus Test for guiding ovarian cancer treatment decisions; and its Prolaris Test for evaluating prostate cancer aggressiveness. 

Ahmedabad, India-based Zydus will now have the exclusive rights to market and sell the tests in India. Financial and other terms of the agreement were not disclosed.

Salt Lake City-based Myriad said earlier this year that the MyRisk and Prolaris tests were key drivers of its hereditary cancer testing business in 2025 and that updated versions of the tests were on deck.

Source: Zydus Lifesciences to Market Myriad Genetics Cancer Tests in India